Malignant pleural mesothelioma Cancer Malignant pleural mesothelioma
Conditions
Interventions
Participants receive either debulking and hyperthermic intraoperative intrathoracic chemotherapy (HITHOC) or talc pleurodesis depending on which trial participating centre they attend. This is determi
Sponsors
University of Catania
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Proven or suspected mesothelioma attending the Policlinico mesothelioma outpatient clinic 2. Patients that have given verbal and written consent to participant 3. Patients with pleural tumour and with associated pleural effusion that are fit enough for VATS pleurectomy/decortication 4. Patients attending Morgani clinic and University of Palermo that are undergoing talc pleurodesis
Exclusion criteria
Exclusion criteria: 1. Unfit for a VATS procedure 2. Previously attempted pleurodesis 3. Without a pleural effusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Participants quality of life will be assessed by the Symptoms and Quality of Life: European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire at baseline and at 3, 6 and 12 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Survival rates of participants will be measured using personal interview or phone calls throughout the whole study period 2. Length of hospital stay will be assessed by case report forms throughout study period during the hospitalisation 3. Complications from the procedure will be assessed by case report forms (CRF) at baseline, 3, 6 and 12 months 4. Recurrence of pleural effusion will be assessed by plain chest radiograph at 3, 6 and 12 months | — |
Countries
Italy
Contacts
Public ContactMarcello Migliore
Outcome results
None listed